Cognivue vs Neurotrack (2026)
Both screen for cognitive impairment, one on dedicated hardware and one in software. Cognivue's Clarity and Thrive devices run self administered tests that adapt to the patient's visual and motor responses and print a report scored against age norms, with an optional machine learning amyloid estimate on Clarity. Neurotrack runs three short assessments in clinic or at home, and Smart Logic chooses what to give next, combines results with EHR context to surface a diagnostic pathway, and drafts a care plan; the company does not say how Smart Logic works. The regulatory picture is closer than it looks. Cognivue's De Novo covered its original device in 2015, and the devices it sells now are listed under an exempt code, so neither current product holds a clearance. Choose Cognivue for self contained screening outside the clinic; choose Neurotrack for a workflow from result to care plan.
- Self administered tests on a dedicated device, scored against age norms.
- Adaptive exercises across memory, executive function, attention and visuospatial ability.
- An optional machine learning amyloid risk estimate, CARM.
- Three short assessments taken in clinic, remotely or at home.
- Smart Logic, which chooses the next assessment and surfaces a diagnostic pathway using EHR context.
- Care plan drafting for mild cognitive impairment and dementia.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Cognivue and Neurotrack are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Cognivue | Neurotrack |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | Not recorded | 2012 |
| Headquarters | Victor, New York, United States | Redwood City, California, United States |
| Website | cognivue.com | neurotrack.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Self-administered computerized cognitive assessment on dedicated devices. Cognivue Clarity, a ten minute test for physicians, and Cognivue Thrive, a five minute screen for pharmacies, hearing care practices and other non-physician settings, run on adaptive psychophysics: each exercise adjusts to the patient's visual and motor responses across subtests of memory, executive function and attention, discrimination and visuospatial ability, entered through a single control wheel, and the device prints a report scored against age norms.
Source: AI Health Index, September 2026
Neurotrack describes itself as a cognitive care enablement platform: digital cognitive assessments, an adaptive layer it calls Smart Logic, and care planning support, sold to help providers assess, diagnose and care for people with mild cognitive impairment and dementia. The assessments are Symbol Match (processing speed and visual attention), Path Points (a digital trail making task for executive function) and Word Recall (verbal memory); the first step takes about three minutes and can be taken in clinic, remotely or at home.
Source: AI Health Index, September 2026
Questions buyers ask
How do Cognivue and Neurotrack work with the EHR?
For Cognivue, the earlier security features document (RES-001-A, 2023) says an administrator can configure the device to create an HL7 message holding the report, or set up a password protected network file share to reach the report folder. The current Gen5 document (RES-002-A, 2025) mentions only printing, by USB or network.
The platform page says Neurotrack integrates directly into existing EHR environments, connects to major EHR platforms, and generates structured documentation that flows automatically into the patient record, including assessment results, DSM-5 aligned documentation and care plans. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Cognivue and Neurotrack handle patient data?
In Cognivue's case, the Gen5 security features document (RES-002-A, 2025) lists the fields Clarity and Thrive store per test: name, date of birth, sex, subtest and domain scores and, optionally, email and phone number. It says they are kept in a local database on the device, reachable only by on-device processes, under full disk AES-256 encryption, with administrators alone able to open older reports.
For Neurotrack, the rest of the lifecycle is looser. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Cognivue and Neurotrack cover?
With Cognivue, the pharmacy and hearing care settings, where the result is read by a non-physician, carry implementation posters rather than published performance.
In Neurotrack's case, the value based care tie is explicit: the health plan page sells the assessments as documentation for V28 HCC risk adjustment, where dementia severity drives the risk score, and cites a national Medicare Advantage plan that made the assessment standard in its home based Annual Wellness Visit program. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Cognivue and Neurotrack?
The authors are the company's Chief Scientific Officer, university colleagues and Cognivue staff. A competitor's analysis of the same Bio-Hermes cohort (Jannati et al., Alzheimer's Research and Therapy, 2025) reported Cognivue at AUC 0.70 for amyloid status, and the company's chief executive published a Matters Arising on that comparison's method (2026).
With Neurotrack, the published evidence the platform page cites is a Frontiers in Aging Neuroscience study reporting 94 percent sensitivity and 90 percent specificity for the Symbol Match and Path Points battery, comparing healthy people with people diagnosed with Alzheimer's disease. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither company publishes a price. Cognivue's De Novo from 2015 covered its original device, and the devices it sells now are listed under an exempt code; Neurotrack describes its product as FDA registered. Neither current product holds a clearance.
Ask both how their result is validated against a clinician's diagnosis.